BidaskClub upgraded shares of Repligen (NASDAQ:RGEN) from a hold rating to a buy rating in a report issued on Friday morning, BidAskClub reports.

A number of other research analysts have also weighed in on RGEN. ValuEngine upgraded Repligen from a buy rating to a strong-buy rating in a research report on Monday, June 17th. Zacks Investment Research lowered Repligen from a buy rating to a hold rating in a research report on Saturday, May 11th. Two analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus price target of $64.20.

NASDAQ:RGEN opened at $83.04 on Friday. The company has a current ratio of 2.18, a quick ratio of 1.84 and a debt-to-equity ratio of 0.03. The stock has a market cap of $3.92 billion, a price-to-earnings ratio of 113.75, a price-to-earnings-growth ratio of 5.12 and a beta of 1.00. Repligen has a 52 week low of $45.00 and a 52 week high of $83.69.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, May 9th. The biotechnology company reported $0.28 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.02. The business had revenue of $60.63 million for the quarter, compared to analysts’ expectations of $55.09 million. Repligen had a return on equity of 6.35% and a net margin of 10.11%. The business’s quarterly revenue was up 35.3% on a year-over-year basis. During the same period last year, the firm earned $0.17 earnings per share. As a group, analysts predict that Repligen will post 0.93 earnings per share for the current fiscal year.

In related news, Director Glenn L. Md Cooper sold 5,000 shares of Repligen stock in a transaction dated Thursday, May 23rd. The stock was sold at an average price of $66.94, for a total value of $334,700.00. Following the completion of the transaction, the director now owns 35,975 shares in the company, valued at $2,408,166.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Karen A. Dawes sold 1,295 shares of Repligen stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $77.35, for a total value of $100,168.25. Following the completion of the transaction, the director now owns 118,329 shares of the company’s stock, valued at approximately $9,152,748.15. The disclosure for this sale can be found here. Company insiders own 1.70% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RGEN. Huntington National Bank purchased a new position in Repligen in the first quarter worth about $25,000. Royce & Associates LP grew its position in Repligen by 40.6% in the first quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 145 shares in the last quarter. Mascoma Wealth Management LLC purchased a new position in Repligen in the first quarter worth about $41,000. Private Capital Group LLC grew its position in Repligen by 675.3% in the first quarter. Private Capital Group LLC now owns 721 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 628 shares in the last quarter. Finally, Bronfman E.L. Rothschild L.P. grew its position in Repligen by 16.8% in the fourth quarter. Bronfman E.L. Rothschild L.P. now owns 1,491 shares of the biotechnology company’s stock worth $79,000 after acquiring an additional 214 shares in the last quarter. Institutional investors own 84.90% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

See Also: Short Selling Stocks, A Beginner’s Guide

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.